![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » GlycoGenesys Enters Into Agreements to Close on Funding
GlycoGenesys Enters Into Agreements to Close on Funding
March 7, 2005
GlycoGenesys, a biotechnology company developing carbohydrate-based drugs, has announced that it has entered into definitive agreements to close on gross proceeds of $6,500,000 from institutions in exchange for issuance of 6,500 shares of convertible, redeemable Series D Preferred Stock, currently convertible into 6,500,000 shares of common stock, and warrants to purchase 6,500,000 shares of common stock currently at $1.23. The terms of the Series D Preferred Stock and warrants will be described in a current report on Form 8-K that the company will file with the Securities and Exchange Commission.
Yahoo News (http://biz.yahoo.com/bw/050304/45389_1.html)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct